459 - Efficacy and Safety of Novel 5-HT4 Agonist DSP-6952 in Patients with Irritable Bowel Syndrome with Constipation: A Randomized, Double-Blind, Placebo-Controlled Early Phase II Study

Phase Ii ◽

Early Phase ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

A twelve-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, phase II study to assess the clinical efficacy of alosetron (GR68755) in male subjects with irritable bowel syndrome

The American Journal of Gastroenterology ◽

10.1016/s0002-9270(01)03784-4 ◽

2001 ◽

Vol 96 (9) ◽

pp. S317 ◽

Cited By ~ 1

Author(s):

E EDWARDS1

Keyword(s):

Phase Ii ◽

Clinical Efficacy ◽

Phase Ii Study ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group ◽

Dose Ranging ◽

Irritable Bowel ◽

Male Subjects

Faculty Opinions recommendation of Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958672.793516776 ◽

2016 ◽

Author(s):

Robin Spiller

Keyword(s):

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Plecanatide, a Novel Uroguanylin Analog: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate Efficacy and Safety in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

The American Journal of Gastroenterology ◽

10.14309/00000434-201410002-01831 ◽

2014 ◽

Vol 109 ◽

pp. S541 ◽

Cited By ~ 16

Author(s):

Philip Miner ◽

Robert DeLuca ◽

Marianela La Portilla ◽

Eveline Padila ◽

William Koltun ◽

...

Keyword(s):

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging ◽

Efficacy and Safety of Additional 200-mg Dose of Celecoxib in Adult Patients With Postoperative Pain Following Extraction of Impacted Third Mandibular Molar: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Japan

Clinical Therapeutics ◽

10.1016/j.clinthera.2012.01.004 ◽

2012 ◽

Vol 34 (2) ◽

pp. 314-328 ◽

Cited By ~ 10

Author(s):

Ken‘ichi Saito ◽

Akihiro Kaneko ◽

Katsuyuki Machii ◽

Hiroyoshi Ohta ◽

Masayuki Ohkura ◽

...

Keyword(s):

Postoperative Pain ◽

Phase Ii ◽

Phase Ii Study ◽

Adult Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Mandibular Molar

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-17-1558 ◽

2017 ◽

Vol 24 (2) ◽

pp. 316-325 ◽

Cited By ~ 7

Author(s):

Axel Grothey ◽

Jonathan R. Strosberg ◽

Lindsay A. Renfro ◽

Herbert I. Hurwitz ◽

John L. Marshall ◽

...

Keyword(s):

Colorectal Cancer ◽

Supportive Care ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Best Supportive Care ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Efficacy and Safety of Tenapanor in Patients With Constipation Predominant Irritable Bowel Syndrome: A 12-week, Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial

The American Journal of Gastroenterology ◽

10.14309/00000434-201710001-00421 ◽

2017 ◽

Vol 112 ◽

pp. S226-S227 ◽

Cited By ~ 4

Author(s):

William D. Chey ◽

Anthony J. Lembo ◽

Paul Korner ◽

Andrew Yan ◽

David P. Rosenbaum

Keyword(s):

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

377 A Randomized, Double-Blind, Placebo-Controlled Trial with a Novel Dual Noradrenergic Reuptake Inhibitor (NARI) and 5-HT3 Antagonist: Results of a Phase II 8-Week Study in Female Patients with Diarrhea Predominant Irritable Bowel Syndrome (D-IBS)

Gastroenterology ◽

10.1016/s0016-5085(08)60240-1 ◽

2008 ◽

Vol 134 (4) ◽

pp. A-50 ◽

Cited By ~ 4

Author(s):

William G. Paterson ◽

Jonathon Springer ◽

Michael O'Mahony ◽

Richard P. Reynolds ◽

Subhas C. Ganguli ◽

...

Keyword(s):

Phase Ii ◽

Reuptake Inhibitor ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Female Patients ◽

Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study

BMC Cancer ◽

10.1186/s12885-017-3295-4 ◽

2017 ◽

Vol 17 (1) ◽

Cited By ~ 14

Author(s):

T. Yokota ◽

T. Ogawa ◽

S. Takahashi ◽

K. Okami ◽

T. Fujii ◽

...

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Phase Ii ◽

Neck Cancer ◽

Oral Mucositis ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease

American Journal of Hematology ◽

10.1002/ajh.23725 ◽

2014 ◽

Vol 89 (7) ◽

pp. 709-713 ◽

Cited By ~ 38

Author(s):

Marvin E. Reid ◽

Amal El Beshlawy ◽

Adlette Inati ◽

Abdullah Kutlar ◽

Miguel R. Abboud ◽

...

Keyword(s):

Sickle Cell Disease ◽

Sickle Cell ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Cell Disease ◽

Double Blind ◽

Double Blind Placebo

Efficacy and Safety of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation: Results from 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trials

Gastroenterology ◽

10.1016/s0016-5085(17)34360-3 ◽

2017 ◽

Vol 152 (5) ◽

pp. S1309-S1310 ◽

Cited By ~ 4

Author(s):

Ronald Fogel ◽

Spencer D. Dorn ◽

Richard Krause ◽

Paul Eng ◽

Robert Kirshoff ◽

...

Keyword(s):

Clinical Trials ◽

Efficacy And Safety ◽

Controlled Clinical Trials ◽

Double Blind ◽

Double Blind Placebo ◽